Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126216 | 1.00 | NAMPT (0.49) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL7117906 | 0.91 | QDPR (0.39) | NAMPTCDK7CDK13CDK12WNT3A | |
| SCHEMBL7508337 | 0.91 | QDPR (0.39) | NAMPTCDK7CDK13CDK12WNT3A | |
| SCHEMBL7122767 | 0.84 | NAMPT (0.39) | NAMPT | |
| SCHEMBL7130227 | 0.84 | NAMPT (0.39) | NAMPT | |
| SCHEMBL7123783 | 0.76 | NAMPT (0.51) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL7514922 | 0.75 | NAMPT (0.48) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL8310327 | 0.74 | — | — | |
| SCHEMBL22325022 | 0.74 | NAMPT (0.71) | NAMPTPDK4CDK7CDK13CDK12 | |
| SCHEMBL7122724 | 0.74 | QDPR (0.40) | NAMPTBRD4WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-0912561-B1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | NAMPT 4578/4885PDK4 3977/4885CDK7 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.